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attend	 for	 clinical	 trial	 screening	 is	 unclear.	 To	 assess	 this,	 we	 retrospectively	









alcohol	 in	 excess,	 10%	 were	 current	 smokers,	 11%	 described	 recreational	 drug	
use,	and	only	48%	had	body	weight	in	the	ideal	range.	Our	data	demonstrate	that	
screening	prior	 to	enrollment	 in	early	phase	clinical	 trials	 identifies	a	range	of	




volunteers”	 before	 assessment	 in	 studies	 targeting	 spe-
cific	populations.	Not	all	volunteers	who	consider	them-
selves	 “healthy”	 are	 eligible	 to	 participate	 in	 clinical	
trials.1
“Healthy	 volunteers”	 are	 usually	 screened	 using	 rig-
orous	clinical	assessment	to	assess	eligibility	prior	to	en-
rollment.2	This	screening	process	may	identify	previously	
unrecognized	 abnormalities	 that	 mean	 an	 individual	 is	






can	 be	 difficult	 and	 needs	 to	 balance	 avoiding	 the	 med-
icalization	 of	 well	 individuals	 with	 spurious	 or	 physio-
logical	abnormalities,	against	the	need	to	act	on	findings	
that	facilitate	the	early	detection	and	treatment	of	disease.	
“Normal”	 ranges	 are	 typically	 statistically	 derived	 from	
healthy	 population	 data	 and	 defined	 as	 two	 standard	
deviations	 around	 the	 mean	 of	 the	 sample	 population.	
Normality	 therefore	 does	 not	 categorically	 infer	 health,	
nor	 does	 an	 abnormal	 value	 always	 indicate	 disease.	
Similarly,	 the	 greater	 the	 number	 of	 tests	 one	 performs,	


















WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?




WHAT QUESTION DID THIS STUDY ADDRESS?
To	describe	 the	 incidence	of	 IFs	 in	1838	“healthy	volunteers”	screened	 for	en-
rollment	 in	 a	 UK	 multicenter,	 phase	 I/II	 severe	 acute	 respiratory	 syndrome-	
coronavirus	2	(SARS-	COV-	2)	vaccine	trial.
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therefore	to	be	expected	in	healthy	volunteers.	The	chal-
lenge	 is	 differentiating	 spurious	 abnormal	 results	 from	
clinically	relevant	findings	of	concern.
An	 incidental	 finding	 (IF)	 has	 been	 described	 as	 a	
finding	 “that	 has	 potential	 health	 or	 reproductive	 im-















might	 not	 otherwise	 access	 health	 care.	 These	 data	 can	










few	 data	 exist	 to	 inform	 the	 incidence	 of	 IFs	 in	 healthy	
volunteers,	 detected	 on	 routine	 physical	 observations,	






Drug	Administration	 (FDA)	 for	 the	definition	and	grad-
ing	of	adverse	events	 in	healthy	volunteers	participating	
in	vaccine	trials	do	provide	parameters	for	abnormal	find-
ings	 post-	enrollment,11	 however,	 there	 is	 no	 such	 guid-
ance	available	 for	 the	definition	of	 IFs	 identified	during	
screening,	or	the	management	of	such	IFs.	Although	the	
ethical	 responsibilities	 of	 researchers	 to	 identify	 and	 act	
on	IFs	have	been	discussed,12,13	without	clear	definitions	
of	 IFs	 it	 is	difficult	 to	ensure	appropriate	and	consistent	














55  years	 (NCT04324606).14	 It	 is	 being	 conducted	 at	 five	





Imperial	 College	 London	 (Imperial);	 Vaccine	 Institute,	
St.	Georges	University	of	London	and	University	Hospital	
NHS	 Foundation	 Trust	 (St.	 Georges);	 and	 University	
Hospitals	 Bristol	 and	 Weston	 NHS	 Foundation	 Trust	
(Bristol).
This	study	was	approved	in	the	United	Kingdom	by	the	
Medicines	 and	 Healthcare	 products	 Regulatory	 Agency	
(reference	 21584/0424/001-	0001)	 and	 the	 South	 Central	
Berkshire	 Research	 Ethics	 Committee	 (reference	 20/
SC/0145).	The	trial	is	being	performed	in	accordance	with	
the	 principles	 of	 the	 Declaration	 of	 Helsinki	 and	 Good	
Clinical	Practice.
Potential	 participants	 were	 recruited	 through	 local	




Material)	 prior	 to	 attending	 a	 screening	 clinic	 appoint-






procedures.	 The	 screening	 appointment	 consisted	 of	 a	
medical	 review,	 which	 included	 a	 medical	 history	 (in-
cluding	 alcohol	 intake	 and	 recreational	 drug	 use)	 and	




urea	 and	 electrolytes,	 and	 liver	 function	 tests	 [LFTs]).	
Urinalysis	was	performed	for	blood,	protein,	glucose,	and,	
in	 women	 of	 childbearing	 potential,	 pregnancy,	 using	
point	 of	 care	 tests.	 All	 laboratory	 assays	 on	 sera	 were	






tial	 testing,	participants	were	able	 to	be	 invited	back	 for	
repeat	 testing	 at	 the	 discretion	 of	 the	 local	 study	 team.	
Primary	 care	 records	 were	 obtained	 to	 corroborate	 the	
medical	history,	examination,	and	laboratory	findings.
The	 study	 was	 open	 to	 male	 and	 female	 volunteers	
aged	between	18	and	55 years.	Exclusion	criteria	 for	 the	
study	 have	 been	 previously	 published	 (Supplementary	
Material),14	however,	briefly,	the	study	excluded:	individ-






mine	 eligibility	 according	 to	 local	 laboratory	 references	
ranges	and	criteria	outlined	in	the	clinical	study	plan	doc-
uments,	which	have	been	previously	published.14
For	 the	purposes	of	 this	paper,	all	 raw	screening	data	
was	pooled	centrally.	Blood	results	were	graded	according	
to	 a	 modified	 version	 of	 the	 US	 FDA	 “Toxicity	 Grading	
Scale	 for	 Healthy	 Adult	 and	 Adolescent	 Volunteers	
Enrolled	in	Preventative	Vaccine	Clinical	Trials,	Guidance	
for	 Industry”11	 that	 is	commonly	applied	 in	studies	con-
ducted	at	the	Oxford	Vaccine	Centre,	University	of	Oxford,	
and	 is	 outlined	 in	 Table  S1.	 Urinalysis	 and	 physical	 ob-
servations	 were	 graded	 according	 to	 criteria	 in	 Table	 1	
and	Table  S3	 respectively.	With	 the	 exception	 of	 alanine	
transaminase	(ALT;	Table S4),	analysis	did	not	account	for	
variations	 in	 local	UKAS	accredited	 laboratory	 reference	







ipation.	 Patients,	 and,	 where	 appropriate,	 their	 primary	
care	givers,	were	informed	of	IFs.
Statistical analysis
Due	to	 the	broad	range	and	 low	frequency	of	 individual	
abnormalities,	descriptive	methods	were	used	to	analyze	










for	 the	 trial	 across	 five	 clinical	 trial	 sites	 in	 the	 United	
Kingdom	 between	 March	 and	 April	 2020.	 One	 hundred	
five	 volunteers	 were	 excluded	 from	 the	 study	 prior	 to	
physical	examination,	blood	or	urine	sampling,	and	were	
excluded	from	further	analysis	(Figure 1).	The	reasons	for	
exclusion	 of	 these	 participants	 included:	 difficulty	 com-
mitting	to	study	visit	schedule,	recent	travel	to	countries	
with	known	coronavirus	disease	 (COVID)	cases,	history	
of	 symptoms	 consistent	 with	 COVID,	 and	 disclosure	 of	
medical	 conditions	meeting	 the	 study	exclusion	criteria.	
Screening	 data	 from	 1838	 participants	 were	 analyzed.	
The	 majority	 of	 volunteers	 was	 screened	 at	 the	 Oxford	
site	(52%,	954/1838;	Table S5).	Physical	observations	data	
were	available	for	98%	(1799/1838),	clinical	examination	
data	 were	 available	 for	 97%	 (1778/1838),	 urinalysis	 data	
were	available	for	97%	(1777/1838),	and	blood	test	results	
were	available	for	90%	(1647/1838;	Figure 1).
T A B L E  1 	 Definitions	used	in	analysis
Definitions























   | 5INCIDENTAL FINDINGS IN HEALTHY VOLUNTEERS
Participants	 were	 predominantly	 White	 (89.7%,	
1640/1828),	 with	 those	 of	 Asian	 or	 mixed	 ethnicity	 the	
next	 most	 common	 groups	 (5.3%,	 96/1828	 and	 0.7%,	
12/1828,	 respectively).	 The	 median	 age	 of	 participants	




60.2%	 (1016/1838)	 of	 participants	 were	 enrolled	 in	 the	
study.	Of	them,	8.1%	(149/1838)	were	eligible	but	not	en-
rolled,	and	19%	(355/1838)	of	participants	were	excluded	
due	 to	 detection	 of	 IFs	 at	 screening.	 Other	 reasons	 for	
exclusion	 included	 weight,	 COVID	 exposure,	 logistical	
factors,	 such	 as	 lack	 of	 telephone	 or	 personal	 transport,	
and	pre-	existing	medical	conditions	(Table S6).
Social factors and obesity
The	majority	of	participants	regularly	consumed	alcohol,	









F I G U R E  1  Consort	diagram	of	
individuals	screened	for	COV001
T A B L E  2 	 Demographics	of	individuals	screened	for	COV001
All Female Male
N 1838 49%	(895/1838) 51%	(943/1838)
Age	(years) Median	(IQR) 34	(27–	44) 34	(27–	44) 34	(28–	44)
18–	30 37%	(679/1838) 39%	(347/895) 35%	(332/943)
31–	40 29%	(542/1838) 26%	(232/895) 33%	(310/943)
41–	55 34%	(617/1838) 35%	(316/895) 32%	(301/943)
Ethnicity White 89.7%	(1640/1828) 91.7%	(818/892) 87.8%	(822/936)
Asian 5.3%	(96/1828) 3.7%	(33/892) 6.7%	(63/936)
Black 0.7%	(12/1828) 0.3%	(3/892) 1.0%	(9/936)
Arab 0.5%	(10/1828) 0.4%	(4/892) 0.6%	(6/936)
Mixed 2.2%	(42/1828) 2.4%	(21/892) 2.1%	(20/936)
Other 1.3%	(24/1828) 1.0%	(9/892) 1.6%	(15/936)
Not	specified 0.3%	(5/1828) 0.4%	(4/892) 0.1%	(1/936)
Abbreviation:	IQR,	interquartile	range.
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Only	 52%	 of	 participants	 had	 an	 ideal	 body	 weight	
(IBW)	 for	 their	 height	 according	 to	 BMI	 recorded	 at	
screening	 (Table  S8).	Women	 were	 more	 likely	 to	 have	
an	IBW	than	men	(p = <0.0001,	Fisher’s	exact	test).	Of	
those	 participants	 with	 a	 BMI	 greater	 than	 25  kg/m2,	
men	 were	 more	 likely	 than	 women	 to	 be	 overweight	
(p = <0.0001,	Fisher’s	exact	 test)	or	obese	(p < 0.0001,	
Fisher’s	exact	test).	9.7%	of	participants	(179/1838)	were	
found	 to	 have	 a	 BMI	 greater	 than	 or	 equal	 to	 30,	 clas-
sifying	them	as	obese	and	this	was	considered	an	IF	in	
further	analyses.
Physical observations and findings on 
clinical examination
16.9%	 of	 patients	 (304/1799)	 had	 an	 IF	 detected	 on	 as-




7%	 (127/1794)	 and	 5%	 (89/1795)	 of	 participants,	 respec-
tively.16	 IFs	 were	 detected	 on	 clinical	 examination	 in	 a	
small	 proportion	 of	 participants	 (0.96%,	 17/1778),	 with	
the	most	common	finding	being	a	systolic	heart	murmur,	
which	 was	 identified	 in	 0.6%	 of	 participants	 (10/1778;	
Table 4).
Blood tests
The	 frequency	 of	 laboratory	 IFs	 at	 screening	 varied	 ac-
cording	to	site,	potentially	reflecting	differences	in	labora-
tory	assays	at	sites	(Table S9).	Laboratory	IFs	were	more	
likely	 to	 be	 detected	 in	 men	 than	 women	 (16%	 vs.	 7%,	
p < 0.0001,	Fisher’s	exact	test).
The	 most	 common	 laboratory	 IF	 at	 screening	 was	
a	 raised	 ALT,	 which	 was	 identified	 in	 5.9%	 of	 partic-
ipants	 (Table  5)	 and	 accounted	 for	 46%	 of	 laboratory	
IFs	 (Table  S10).	 Elevated	 ALT	 was	 more	 likely	 to	 be	
detected	 in	 men	 than	 women	 (p  <  0.0001,	 Fisher’s	
exact	test;	Table S11).	There	was	a	weak	correlation	be-
tween	BMI	and	ALT	(n = 1634,	r = 0.299,	p < 0.0001,	
Spearman	 Rank)	 and	 ALT	 and	 reported	 weekly	 alco-
hol	intake	(n = 1636,	r = 0.118,	p < 0.0001,	Spearman	
Rank).








related	 to	 both	 ambient	 air	 temperature	 and	 a	 delay	 in	









Three	 percent	 of	 participants	 (53/1700)	 had	 normal	
bloods	at	screening	and	then	an	IF	detected	on	the	day	of	






































Elevated	 ALT	 was	 the	 most	 common,	 new,	 IF	 de-
tected,	 accounting	 for	 40%	 of	 new	 abnormalities	 at	
enrollment	 (Table  S13).	 All	 of	 these	 were	 grade	 1	 in	








routinely	 re-	tested	 to	 assess	 for	 resolution,	 however,	
this	did	 take	place	 for	 some	participants	according	 to	
clinician	 discretion.	 Twenty-	three	 participants	 with	
laboratory	 IFs	 at	 screening	 were	 subsequently	 en-
rolled	 with	 normal	 bloods	 on	 the	 day	 of	 vaccination,	
after	 repeat	 testing	 showed	 resolution	 of	 screening	
IFs	(Table S14).	Thirty	percent	(7/23)	of	 these	 labora-
tory	IFs	were	grade	2	elevated	ALT	(ALT	>2.5 × ULN)	
and	 35%	 (8/23)	 were	 grade	 2	 or	 3  hypokalemia	 (2.5–	
3.1 mmol/L;	Table S16).
Urinalysis
Hematuria	 was	 the	 most	 common	 IF	 detected	 on	 urine	
analysis,	 affecting	 7%	 of	 participants	 (116/1768;	 Table  6).	
Women	 were	 more	 likely	 to	 have	 hematuria	 detected	













Proteinuria	 was	 detected	 in	 2%	 of	 participants	
(32/1765).	There	 was	 no	 difference	 in	 the	 prevalence	




tients	 for	 whom	 a	 sample	 was	 retested	 then	 had	 no	
proteinuria.
Glycosuria	 was	 detected	 in	 0.3%	 of	 participants	
(6/1766),	 and	 0.1%	 (1/854)	 of	 female	 participants	 had	 a	
positive	urine	pregnancy	test.
Proportion of population with 
incidental findings
27.7%	 of	 participants	 (510/1838)	 had	 at	 least	 one	 IF	 de-
tected	 at	 screening.	 Overall,	 around	 one	 in	 four	 healthy	
volunteers	 had	 an	 IF.3.3%	 of	 participants	 (61/1838)	 had	









Hyponatraemia * 0.06%	(1) 0%
Hypernatraemia * 0% 0%
Hypokalaemia * 0.61%	(10) 0.30%	(5)
Hyperkalaemia * 0.18%	(3) 0.06%	(1)
Urea * 0.43%	(7) B




ALT 5.34%	(88) 0.24%	(4) 0%
Alk	phos 0.18%	(3) 0% 0%
Albumin * 0% 0%
Haematology
Anaemiaa * 0.24%	(4) 0%
Leucocytosis * 0% 0%
Leucopenia * 0% 0%
Thrombocytopenia * 0.24%	(4) 0.06%	(1)
Neutropenia * 0.61%	(10) 0%
Lymphopenia * 0% 0%
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clinical	 trials.2	 This	 figure	 is	 likely	 an	 underestimate	 of	
the	true	frequency	to	be	expected	in	a	normal	distribution	
of	 individuals	 aged	 18–	55  years	 because	 younger	 adults	
were	 over-	represented	 in	 our	 population	 (age	 range	 27–	








The	 authors	 identified	 previously	 undiagnosed	 medical	
conditions	 in	 9.7%	 of	 volunteers	 once	 alcohol	 excess,	 ex-
tremes	of	weight,	or	the	presence	of	tattoos	(considered	a	
potential	surrogate	for	hepatitis	C	infection)	were	excluded.	





(0.01%,	 1/1293),	 and	 thyroid	 dysfunction	 (0.5%,	 7/1293).	
The	 second	study	of	990	 individuals	 screened	 for	partici-
pation	in	early	phase	vaccine	trials	at	The	Jenner	Institute,	
University	 of	 Oxford	 between	 1999	 and	 2010,	 reported	











































































































































































































































































































































































A	 key	 finding	 of	 our	 study	 is	 the	 high	 prevalence	 of	
elevated	ALT	in	our	population	affecting	5.9%	of	screened	
individuals,	 with	 men	 more	 affected	 than	 women.	 The	
considerable	proportion	of	our	population	who	were	over-
weight	 and	 consumed	 excessive	 alcohol	 may	 have	 con-





on	 retesting	 and	 others	 newly	 developing	 elevated	 ALT	
on	the	day	of	vaccination.	Although	it	has	been	reported	











PIS	 and	 consent	 forms	 for	 early	 phase	 studies	 com-
monly	 highlight	 the	 risk	 of	 identifying	 blood-	borne	 vi-
ruses	on	screening.	However,	in	our	cohort,	the	chance	of	
identifying	evidence	of	a	potential,	new	HIV,	hepatitis	B,	
or	 hepatitis	 C	 infection	 was	 low	 (1	 in	 238	 screened	 par-
ticipants)	compared	to	 identification	of	an	elevated	ALT	
(1	 in	 17	 screened	 participants).	We	 suggest	 that	 the	 rel-
ative	 likelihood	 of	 abnormal	 findings	 as	 well	 as	 the	 sig-
nificance	of	potential	abnormal	findings	should	influence	
















physician	 in	 highlighting	 and	 advising	 about	 unhealthy	
social	 habits	 (for	 example,	 advice	 about	 smoking	 cessa-
tion	or	 recommended	alcohol	 intake)	and	consideration	
made	of	participants’	perception	of	such	advice.
One	 of	 the	 main	 limitations	 of	 this	 study	 is	 that	 the	








Early	 phase	 clinical	 trialists	 are	 rightly	 cautious	 and	















•	 Volunteers	 should	 be	 counselled	 prior	 to	 con-
sent	about	the	high	likelihood	of	identifying	an	
incidental	 finding	 on	 screening	 and	 the	 steps	
that	would	be	undertaken	in	this	event.
•	 Clinical	investigators	have	a	duty	of	care	to	en-
sure	 potentially	 clinically	 significant	 findings	
are	appropriately	communicated	with	the	par-
ticipant	and	where	appropriate	followed	up	and	
communicated	 with	 the	 volunteer’s	 primary	
healthcare	provider.
•	 Clarification	 is	 needed	 as	 to	 whether	 duty	 of	
care	of	a	trial	physician	should	extend	to	advice	
about	the	impact	of	lifestyle	choices.
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repeat	testing,	as	our	data	demonstrate.	Given	that	volun-
teer	recruitment	commonly	limits	study	progress,27	repeat	
testing	 of	 abnormalities	 of	 questionable	 clinical	 signifi-
cance	can	help	prevent	unnecessary	exclusion	of	healthy	























AJP	 is	 the	 Chief	 Investigator	 of	 UK	 studies	 of	 ChAdOx	
nCoV-	2	vaccine.	The	University	of	Oxford	has	entered	into	
a	 partnership	 with	 AstraZeneca	 on	 coronavirus	 vaccine	
development.	SNF	acts	as	UK	Chief	Investigator	for	other	
commercial	 and	 non-	commercial	 COVID-	19	 vaccines	
studies	 (Janssen	adult	and	paediatric	COVID-	19	vaccine	
trials,	Valneva	COVID-	19	vaccine	trials,	Oxford/AZ	pae-
diatric	vaccine	 trial	and	 the	 Imperial	College	COVID-	19	
vaccine	trial).	PTH	acts	as	UK	Chief	Investigator	for	the	
Novavax	 COVID	 19	 vaccine	 trial	 and	 as	 an	 investigator	
for	 other	 commercial	 and	 non-	commercial	 COVID-	19	
vaccine	trials	(Valneva	COVID-	19	vaccine	trials,	Oxford/
AZ	 paediatric	 vaccine	 trial,	 Pfizer	 pregnancy	 COVID-	19	
trial	 and	 the	 Imperial	 College	 COVID-	19	 vaccine	 trial).	
KMP	acts	as	Chief	Investigator	and	investigator	for	other	
commercial	 and	 non-	commercial	 COVID-	19	 vaccine	
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